Evidence map›Paper›PMID 40087607›Full record

ArticleBMC infectious diseases2025

Antimicrobial strategies of lower respiratory tract infections in immunocompromised patients based on metagenomic next-generation sequencing: a retrospective study.

Beibei Meng, Haichao Liu, Qinliang Wu, Lei Qu, Congzheng Mao, Fang Yang, Tianzhou Lan, Juan Fang, Zhenhong Hu, Yao Fang

Abstract read
In one paragraph

Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Beibei Meng *School of Medicine, Wuhan University of Science and Technology, Wuhan, Hubei, 430065, China.
Haichao Liu *Department of Respiratory and Critical Care Medicine, General Hospital of Center Theater of PLA, Wuhan, 430070, China.
Qinliang WuDepartment of Clinical Laboratory, General Hospital of Center Theater of PLA, Wuhan, 430070, China.
Lei QuDepartment of Respiratory and Critical Care Medicine, General Hospital of Center Theater of PLA, Wuhan, 430070, China.
Congzheng MaoDepartment of Respiratory and Critical Care Medicine, General Hospital of Center Theater of PLA, Wuhan, 430070, China.
Fang YangDepartment of Respiratory and Critical Care Medicine, General Hospital of Center Theater of PLA, Wuhan, 430070, China.
Tianzhou LanSchool of Medicine, Wuhan University of Science and Technology, Wuhan, Hubei, 430065, China.
Juan FangSchool of Medicine, Wuhan University of Science and Technology, Wuhan, Hubei, 430065, China.
Zhenhong HuSchool of Medicine, Wuhan University of Science and Technology, Wuhan, Hubei, 430065, China. hph87217479@sina.com.
Yao FangSchool of Medicine, Wuhan University of Science and Technology, Wuhan, Hubei, 430065, China. lolfang@sina.cn.

Funding

Natural Science Foundation of Hubei Province JCZRYB202500657Wuhan Young and Middle-aged Medical Backbone Talent Project 2020 2020-55Young Talent Project of General Hospital of Center Theater ZZ20231693
6 · The paper itself

Abstract

backgroundImmunocompromised patients with Lower Respiratory Tract Infections (LRTI) frequently encounter a diverse range of pathogenic infections, characterized by rapid disease progression and significant mortality rates due to reckless or excessive utilization of antibiotics. Therefore, it is crucial to promptly and accurately identify the causative microorganisms for pathogen diagnosis and clinical decision-making. The objective of this study is to evaluate the clinical applicability of metagenomic next-generation sequencing (mNGS) in the diagnosis and management of LRTI, as well as its impact on empirical antibacterial therapy for patients with varying immune statuses.

methodsWe conducted a comparative analysis of positivity rate, detection accuracy, pathogen spectrum, duration of treatment (DOT), and antibiotic management in a cohort of 283 patients diagnosed with lower respiratory tract infections.

resultsThe positive detection rate was higher in mNGS compared to conventional culture in both immunocompetent group (89.92% vs. 28.57%, P < 0.001) and immunocompromised group (84.44% vs. 33.33%, P < 0.001). The antibiotic escalation in the immunocompromised group was more frequent than that in the immunocompetent group (49.00% vs. 31.00%, P = 0.018), but no difference was observed for antibiotic de-escalation (20.00% vs. 15.00%, P = 0.458).

conclusionsThe application of mNGS can significantly enhance the pathogen detection rate and optimize antimicrobial drug management in immunocompromised patients with LRTI.

Indexed as

Anti-Bacterial AgentsHigh-Throughput Nucleotide SequencingImmunocompromised HostMetagenomicsRespiratory Tract InfectionsAdultAgedAged, 80 and overBacteriaFemaleHumansMaleMiddle AgedRetrospective StudiesAnti-Bacterial AgentsAntibiotic managementImmune statusLower respiratory tract infections (LRTI)Metagenomic next-generation sequencing (mNGS)Pathogen identification

Identifiers

PMID40087607
PMCPMC11907972

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.